The leukocyte adhesion deficiency (LAD) syndromes are rare genetically determined conditions with challenging clinical features. These immunodeficiencies also provide insights that are broadly relevant to the biology of leukocytes, platelets, intercellular interactions, and intracellular signaling. Recent discoveries merit their review in the context of existing knowledge.
INTRODUCTION
The leukocyte adhesion deficiency (LAD) syndromes are primary immunodeficiency disorders that are classified as defects in adhesion-dependent functions of myeloid phagocytes, principally polymorphonuclear leukocytes (PMNs; neutrophils) and monocytes [1, 2] . Although rare ( 1 : 1 000 000 births), their investigation has yielded fundamental insights relevant to inflammation, hemostasis, and regulation of cell-cell interactions, in addition to new knowledge applicable to clinical care. The LAD syndromes result from genetic alterations in the number or activation of integrins on leukocytes or in fucosylation of selectin ligands including P-selectin glycoprotein 1 (PSGL-1), a major leukocyte adhesion molecule that binds P-selectin, E-selectin, and L-selectin [3, 4, 5 & ] (Fig. 1 ). Human and murine myeloid leukocytes express integrins -which are critical and widely distributed adhesion molecules [6, 7] -of several subclasses in cell-specific patterns. Members of the b 2 subclass of integrins (CD11/CD18; sometimes called the leukocyte, or leukocyte-specific, integrins because expression is restricted to these cells) are basally expressed by neutrophils, monocytes, and other circulating myeloid leukocytes (Fig. 1) , and are essential for temporally and spatially regulated adhesion of these cells to endothelial cells of postcapillary venules and, under some conditions, other systemic vessels in response to inflammatory signals [3, 4, [8] [9] [10] [11] 12 P-selectin glycoprotein 1 and other selectin ligands are -like integrins -basally expressed on PMNs, monocytes, and other leukocytes including lymphocyte subclasses. PSGL-1 contributes to P-selectin-dependent interactions of leukocytes with activated platelets [25] , in addition to their adhesion to activated endothelium ( Fig. 2 ) and in leukocyte-leukocyte interactions [5 & ]. The paramount clinical feature common to the LAD syndromes is recurrent bacterial infection that is often severe, life-threatening, and difficult to treat [2,26 && ]. Infection by other microorganisms also occurs. Recurrent infection is a consequence of defective leukocyte adhesion to activated endothelium that impairs migration of leukocytes into tissues at sites of microbial entry and injury [2-4, 
KEY POINTS
Leukocyte adhesion deficiency (LAD) syndromes are rare genetic immunodeficiency disorders that are caused by defects in adhesion and signaling of leukocytes and platelets. Each LAD is dominated by impaired interactions of neutrophils and monocytes with endothelial cells, but also involves other cells and other functional responses.
LAD-I results from absent or reduced expression of b 2 integrins, a critical subset of integrin heterodimers that is restricted to leukocytes.
LAD-II is caused by mutations in a Golgi-specific GDPfucose transporter, leading to impaired fucosylation of ligands that are recognized by selectins and mediate leukocyte adhesion and signaling.
LAD-III results from impaired inside-out signaling of b 1 , b 2 , and b 3 integrins, yielding defective leukocyte adhesion and signaling and a Glanzmann-like bleeding tendency, and is caused by mutations in FERMT3 and consequent deficiency of KINDLIN-3. (2), tight adhesion and arrest resistant to shear (3), and emigration of adherent leukocytes across the endothelium in response to inflammatory signals (4) [3, 10] . In-vivo experiments complemented in-vitro models and confirmed that similar events occur in postcapillary venules and other vessels. Studies of PMNs from patients and animal models indicate that there is defective rolling in LAD-II (step 1), defective integrin activation and consequent tight adhesion in LAD-III (step 2), and defective tight adhesion in LAD-I (step 3). Each defect impairs the ability of PMNs to transmigrate to sites of extravascular infection or injury (step 4). More recent studies, many involving genetically altered mice, have refined the cascade paradigm, and added nuances to the stepwise events illustrated here (reviewed in [8,9,11,12 & ]. For example, b 2 integrins, particularly a L b 2 , mediate early slow rolling of PMNs, in addition to later tight adhesion and arrest [8,13 & ]. Furthermore, there is evidence that engagement of PSGL-1 on PMNs can trigger insideout signaling of b 2 integrins; thus, this is a second mechanism for b 2 integrin activation in addition to localized signaling of PMNs by endothelial presentation of activating agonists recognized by G-protein-coupled receptors [3, 8, 10] . This was first indicated by potentiation of b 2 integrin activation triggered via G-protein-coupled receptors when selectin ligands on human PMNs were engaged by purified P-selectin [14] and more recently supported by studies in murine models of inflammation [15] . Additional recent experiments demonstrate that PMN rolling on P-selectin or E-selectin can partially activate a L b 2 by engaging PSGL-1 [8,9,13 & ,16-18] . Another new feature of the adhesion cascade is evidence for intraluminal crawling of monocytes and PMNs mediated by binding of a M b 2 to ICAM-1, occuring after rolling and arrest and prior to emigration [8, 11] . Intraluminal gradients of chemokines may form, contributing to differential activation of b 2 integrins on PMNs [11] . New facets of extravasation of PMNs and transmigration through subendothelial matrix mediated by b 1 and b 2 integrins have been identified [8,11,12 & ,19 && ]. Although it is not known that all of these newly identified events occur in the targeting and emigration of human PMNs in clinical infection and inflammation, it is clear that there are intricate features of adhesive interactions mediated by selectin ligands and integrins on PMNs that may be disrupted in a complex fashion in LAD syndromes. The adhesion and signaling paradigms for monocytes and other leukocytes [12 & ,20] are also likely to be further refined. ICAM-1, intracellular adhesion molecule; LAD, leukocyte adhesion deficiency; PMN, polymorphonuclear leukocyte; PSGL-1, P-selectin glycoprotein ligand-1.
Integrins

Normal
Present
integrins was normal and defects in selectin ligands were excluded [3, [34] [35] [36] [37] (Table 1) . Over 80 mutations, many occurring in a 240-residue region encompassed by exons 5-9 in b 2 that is common to all integrin b subunits, have been cataloged [28 && ]. Severe (<2% expression of b 2 integrins) and moderate (2-30% expression of b 2 integrins) LAD-I phenotypes occur [31] . Very rarely, a mutation causes nonfunctional but normally expressed b 2 integrins [ [30, [39] [40] [41] . A sibling of patient 2 with a similar clinical presentation and the same FERMT3 mutation is reported in [39] . Osteopetrosis was not reported in any of these index patients. N.R., not reported. ICAM-1, intracellular adhesion molecule; LAD, leukocyte adhesion deficiency; PMN, polymorphonuclear leukocyte.
inflammation and repair [22, 55, 56] , in addition to defects in tissue surveillance and defense by neutrophils and monocytes (Fig. 2) . The efficacy, indications, and biologic strategies for hematopoietic stem cell transplantation in patients with severe and moderate LAD-I are under evaluation (reviewed in [26 && ,31,57]). Mouse models of b 2 integrin deficiency have provided useful insights and new approaches to explore the biology of LAD-I [22, 29, 55, 56, 58, 59] . For example, murine models [56,60,61 & ] may yield answers to outstanding questions regarding T cell and adaptive immune responses in LAD-I [29, 32] .
LAD-I causes deficient expression of each of the four members of the b 2 integrin subfamily: a L b 2 (CD11a/CD18, LFA-I), a M b 2 (CD11b/CD18, MAC-I, CR3), a X b 2 (CD11c/CD18, p150/95), and a D b 2 (CD11d/CD18) [ [35] . In LAD-III there is impaired adhesion of PMNs to endothelial cells and to immobilized ligands for b 1 or b 2 integrins (fibronectin, fibrinogen, ICAM-1, others) when the leukocytes are stimulated with agonists recognized by G-protein-coupled receptors [N-formylmethionylleucylphenylalanine (FMLP); plateletactivating factor (PAF); interleukin 8 (IL-8); others]. Defective tight adhesion of LAD-III PMNs, triggered when they are rapidly activated by agonists that are presented by inflamed endothelial cells [3, 10] , has been documented under conditions of flow [37] . This was identified as a defining characteristic of LAD-III [38] . (c) Mutations in FERMT3 have been found in all LAD-III patients in whom genotyping has been reported. Identified mutations at the nucleotide level in primary leukocytes or Epstein-Barr virus-transformed lymphocytes are illustrated. These include: nonsense (a), splice site (b), insertion (c), nonsense (d), misense (e), deletion (f), splice site (g), nonsense (h), nonsense (i), splice site (j), and nonsense (k) mutations. A hotspot in exon 12 involving 24 nonsense alleles in 12 families of Turkish origin (Anatolia) indicates a founder effect [28 && ]. Sequences in exons 7-13 and exons 14-15 encode the split F 2 domain and the F 3 subdomain of KINDLIN-3, respectively, which appear to be functionally important in molecular interactions of KINDLIN-3 with integrin b subunit cytoplasmic tails [44-46,47 && ]. Nevertheless, no KINDLIN-3 protein has been detected in primary leukocytes or platelets from any of the LAD-III patients reported to date. See [28 && ,30,38-40,45,48-52] for details and genotype-phenotype correlations. A new mutation in exon [15] has recently been reported in abstract form [53] . Organization of the FERMT3 gene and KINDLIN-3 domain structure have recently been reviewed [28 && ,54]. ICAM-1, intercellular adhesion molecule; LAD, leukocyte adhesion deficiency; PMN, polymorphonuclear leukocyte. of b 2 integrins continue to be discovered. Differential activities of a L b 2 and a M b 2 in PMN adhesion and transmigration (Fig. 2) have recently been identified, based in part on intensive study of a L b 2 [62] , which is a prototype integrin [24 & ]. The most recently identified member of the b 2 subfamily is a D b 2 [63] . Its biology is less well defined than that of the other b 2 integrins. Experiments in mice with targeted deletions of the a D subunit and, consequently, absent expression of a D b 2 , indicate that it has intricate activities in host defense, immune regulation, and inflammatory injury [21, 64] . Expression of a D b 2 is said to be restricted to subsets of macrophages [28 && ,62], but this is based on the pattern of basal expression in mice [21, 64] , which is different from the pattern of expression in humans ( [63] ; our unpublished studies). Nevertheless, a D b 2 on macrophages appears to be important in both experimental animals and humans [21, 65] .
New activities of PMNs and monocytes involving b 2 integrin-mediated adhesion and signaling also continue to be discovered [22,23 & ,66-69] . It is possible that some of these functions, or b 2 integrin activities yet to be identified, are altered in LAD-I. Because integrins are also molecular effectors in inflammatory tissue injury [11] , identification of new b 2 -dependent activities of myeloid leukocytes may have relevance beyond LAD syndromes.
LAD-II: A DEFECT IN FUCOSYLATION OF SELECTIN LIGANDS LEADING TO IMPAIRED SELECTIN BINDING AND SIGNALING
Defects in fucosylation of oligosaccharides including sialyl Lewis X, which is present on PSGL-1 and other key leukocyte glycoconjugates, were previously identified as the molecular basis of LAD-II (reviewed in [3, 31] ). A human gene encoding a guanosine diphosphate (GDP)-fucose-specific transporter present in the Golgi membrane, SLC35C1, was subsequently cloned and is mutated in LAD-II (also termed congenital disorder of gylcosylation IIc), which is much less common than LAD-I [26 && ,28 && ,31, [70] [71] [72] [73] [74] [75] . Mutations resulting in defective function, or dual defects in function and subcellular localization, have been identified [74] . Decreased fucosylation of selectin ligands on leukocytes resulting from mutations in SLC35C1 (Fig. 1 ) leads to their impaired tethering and rolling on activated endothelial cells in LAD-II (Fig. 2 8, 9] and, possibly, other functional responses of leukocytes [29] in LAD-II.
Targeted deletion of slc35c1 in mice resulted in loss of GDP-fucose import into the Golgi lumen and yielded a complex phenotype with features similar to LAD-II, including neutrophilia, monocytosis, and leukocyte adhesion defects [76] . A second slc35c1 À/À mouse model also demonstrated phenotypic features consistent with LAD-II, and provided information on differential effects on myeloid leukocyte and T-lymphocyte targeting in vivo [77] . Treatment of cultured cells from slc35c1 À/À animals with fucose resulted in partial rescue of fucosylation of glycoconjugates [76] . Orally administered fucose has corrected features of LAD-II in some, but not all, humans in which this approach has been studied (reviewed in [26 && ]), and resulted in appearance of the fucosylated erythrocyte H antigen and autoimmune neutropenia in one individual [73] .
The cellular defects and molecular mechanisms causing growth impairment and psychomotor retardation in LAD-II are yet to be defined [26 && ]. These features may be more severe than immunodeficiency in older patients [26 && ,75]. (Figs 1-3) . In contrast to LAD-I, b 2 integrins are expressed at expected or near-normal levels (Fig. 1 ). In addition, they are functional, indicating a defect in inside-out signaling [3, 29] . Inside-out signaling of integrins induces transition from an inactive, or low-affinity, state to one that allows avid binding of ligands, and is sometimes termed activation [44] . Furthermore, there is a defect in inside-out signaling of b 1 integrins on activated leukocytes from patients with LAD-III ( [3, 31] ; also see below). In striking contrast to other LAD syndromes [3, 26 && ,27 & ,29], patients with LAD-III also have a bleeding tendency similar to that in Glanzmann thrombasthenia [78] and defective inside-out signaling of integrin a IIb b 3 , which is the major integrin mediating aggregation and adhesion of platelets [79] (Tables 1 and 2; Fig. 3 39, 40, [48] [49] [50] [51] [52] 80] . Analysis of defects in function of primary leukocytes and platelets from patients with LAD-III has been a critical feature of these investigations (Table 2) .
LAD-III: DEFECTIVE INSIDE-OUT SIGNALING OF MULTIPLE INTEGRINS
Independently, studies in genetically altered mice demonstrated that kindlin-3, a cytoplasmic protein, is required for activation of b 1, b 2 , and b 3 integrins and that its targeted deletion yields leukocyte and platelet adhesion defects that phenocopy those in LAD-III [83 & ,84] -a breakthrough in the field. Prior to these observations, the molecular defect(s) in inside-out signaling [44] that causes LAD-III was an unsolved mystery [3,27 & ,29]. After reports of kindlin-3 À/À mice [83 & ], genotyping of patients with LAD-III rapidly identified mutations in FERMT3 and deficiency of its protein product, KINDLIN-3, in cells from LAD-III patients [30, 40, 48, 50] . FERMT3 mutations have now been found in all patients with LAD-III in whom genotyping has been reported [30, 39, 40, [48] [49] [50] [51] [52] [53] 80] (Fig. 3c ).
On the basis of studies of genetically altered mice [85, 86] and patients with LAD-III [87] , it was proposed that mutations in CALDAGGEF1 (RASGRP2) leading to impaired RAP-1 signaling are a molecular cause of LAD-III (reviewed in [4, 44, 88] ). Genotyping of patients with LAD-III from seven Turkish families, the most common background of patients with this syndrome [31] , yielded three sequence variations, including alterations in CALDAGGEF1 and FERMT3, but unequivocal evidence that mutations in FERMT3 and deficiency of KINDLIN-3 are sufficient to cause [34] [35] [36] [37] 39, 48, 80] Aggregation stimulated by GPCR agonists or PMA [35, 48] Transmigration across resting and cytokine-stimulated endothelial monolayers [34] Chemotaxis in response to GPCR agonists [35] Spreading [48, 52] Monocytes Adhesion of cells in mixed mononuclear cell or mixed leukocyte suspensions (percentage of monocytes not reported) [49, 51] Adhesion, spreading, differentiation of isolated monocytes [39] T or B lymphocytes Spontaneous or stimulated adhesion to purified ICAMs, VCAM-1, fibronectin; adhesion to cytokine-stimulated endothelial cells under shear [36, 37, 40, 41, 45, 81] Transendothelial migration under shear [37] Aggregation [34, 48] Spreading on purified ICAM-1 or dendritic cells [52, 81] Platelets Aggregation mediated by agonists that induce activation of integrin a IIb b 3 [34] [35] [36] 48, 51, 52] Soluble fibrinogen binding [36, 48, 51] Pac-1 antibody binding [34, 36] Clot retraction [35] Adhesion and spreading on immobilized fibrinogen [48, 49, 51] Integrin a 2 b 1 -mediated degranulation [51] Integrin
The table lists selected functional responses and is not comprehensive. Additional assays and details are also included in the cited reports. Also see Fig. 3 . In some studies variations in functional responses were detected when cells were activated with phorbol esters compared to activation with GPCR agonists [52] , but in most studies the results were concordant. Many studies also utilized immortalized lymphoblasts or T-cell clones derived from LAD-III patients and family members, or controls [34] [35] [36] [37] 45, 48, 51] . There can be differences in the responses of transformed lymphocytes versus those of primary cells [34, 49, 51] , but the results have commonly been consistent with defective inside-out signaling of multiple integrins in experiments using immortalized or cloned cell lines. The platelet responses listed include functional activities that are classically defective in Glanzmann thrombasthenia (aggregation, fibrinogen binding, Pac-1 binding, and clot retraction [79] ). In addition, altered function of integrin a 2 b 1 has been reported [51,82 & ], consistent with KINDLIN-3 deficiency (see text) and potentially contributing to severity of bleeding in LAD-III [82 LAD-III [30] . Furthermore, patients with LAD-III and mutations in FERMT3 but without variations in CALDAGGEF1 have been identified [30, [38] [39] [40] 48] , and engineered expression of KINDLIN-3, but not CALDAGGEF1, has rescued adhesion deficiency in cells derived from LAD-III patients [39, 40, 48, 88] . The impact of variations in CALDAGGEF1 on functions of leukocytes and platelets in patients who also have mutations in FERMT3 remains controversial [26 && ,28 && ,41,49,54,87], although it is possible that isolated mutations in the CALDAG-GEF1-regulated pathway -or in other inside-out signaling intermediates yet to be identified -could cause LAD-III [4, 88] . The functional impact of mutations in FERMT3 and deficiency of KINDLIN-3 is, however, clear.
KINDLIN-3 deficiency also likely contributes to impaired outside-in signaling by leukocyte and platelet integrins [46,83 & ], a key feature of their biology [6, 79] , in LAD-III. Further, deficiency of KINDLIN-3 likely contributes to features of LAD-III apart from impaired leukocyte interaction with endothelium and platelet functional defects. In kindlin-3 À/À mice, defective inside-out signaling of b 1 , b 2 , and b 3 integrins on monocyte-lineage osteoclasts impairs podosome formation and bone resorption, culminating in osteopetrosis [89 && ] as occurs in some patients with LAD-III [45, 48, 50, 51, 80, 87] . Recently, KIND-LIN-3 was reported to be present in human erythrocytes, as the ortholog is in mice [90] , and its deficiency proposed to be a cause of poikilocytosis and anemia in LAD-III [49] . Anemia was reported in three of the four index patients (Table 1) , although the contributions of bleeding and other causes were not determined.
A substantial body of evidence indicates that integrin cytoplasmic domains -particularly the b subunit cytoplasmic tail -regulate conformational changes that result in ligand binding, and are key 'trigger' regions in inside-out signaling (reviewed in [44] ). KINDLIN-3, which is one of three kindlin orthologs in mammals, binds to cytoplasmic domains of b 1 , b 2 , and b 3 integrins [46,83 & ,84] and works in cooperation with TALIN 1, a cytoplasmic protein that links integrin b tails to the actin cytoskeleton (reviewed in [44,47 && ]). The actin cytoskeleton is critical for stabilization of integrin bonds and platelet and leukocyte adhesiveness [91] , but early experiments indicated that impaired actin polymerization does not underlie defective adhesion of neutrophils in LAD-III [34] [35] [36] . TALIN 1 has an N-terminal head domain (THD) with a FERM (4.1, ezrin, radixin, moesin) motif and four subdomains in its structure; overexpression of the THD is sufficient to activate b 1 , b 2 , and b 3 integrins [44] . This and other observations demonstrate that TALIN 1 is critical in inside-out signaling of integrins on leukocytes and platelets (reviewed in [44, 47 && ]). Nevertheless, TALIN 1 is widely expressed, and its mutation or deletion is unlikely to account for the unique cellular defects in LAD-III; global deletion of talin 1 in mice is embryonic lethal [47 && ]. KINDLIN-3, on the contrary, is largely restricted to blood cells [46, 54] , although it is also found in endothelial cells [92] . KINDLIN-3 and other kindlins contain a FERM domain similar in sequence to that in TALIN but in which the F 2 subdomain is split by an embedded pleckstrin homology domain [46, 54] . The interrupted kindlin FERM domain and, particularly, the F 3 subdomain mediate binding to integrin b tails at a motif that is distinct, and distal to, the THD-binding region (reviewed in [44, 46, 47 && ]). The mechanisms by which KINDLIN-3 and TALIN cooperatively modify integrin conformation, affinity, and avidity, and interact in inside-out signaling and activation of b 1 , b 2 , and b 3 integrins on platelets and leukocytes are not yet precisely defined [44, 46, 47 && ] and are being aggressively explored [93] [94] [95] [96] [97] [98] [99] -an explosion of work triggered, in part, by recognition that KIND-LIN-3 deficiency is the molecular basis for LAD-III.
CONCLUSION
Rare maladies of humans teach observant physicians and translational biologists much, as was recognized by Harvey and Garrod [3] . There have been many such lessons from the LAD syndromes. Ongoing investigations of the intricate nature of integrins, selectin binding and signaling, and inside-out and outside-in signal transduction mechanisms suggest that other such lessons are in the offing, and that the molecular mechanisms that underlie LAD-I, LAD-II, and LAD-III will be further illuminated.
